The global neurodiagnostics market size is expected to reach USD 22.99 billion by 2030 ,registering a CAGR of 3.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. Key factors driving the market growth include increasing prevalence of neurological diseases due to demographic changes and growing awareness of their management. In addition, consistent technological modifications coupled with increased preference for novel diagnostic technologies will further fuel the market. The economic burden of neurological diseases is extremely high on society and governments with around 1 billion people suffering globally.
Among all the neuroimaging techniques, computed tomography has the largest market share followed by Magnetic Resonance Imaging (MRI). Computed Tomography (CT) uses ionized radiations for the purpose of creating images, whereas MRI uses radio waves in a magnetic field. Neuroimaging techniques are used to detect brain injuries, developmental malformations in the brain area, vascular irregularities that may lead to stroke, epilepsy, etc.
Biomarkers are an important part of in vitro diagnostics for neurological disorders as their development is targeted at the early disease diagnosis with information about the nervous system. Although biomarkers are not commercially available in the market, their use is confined to clinical research settings. For instance, ELISA tests for Tau protein are available in clinical studies of Alzheimer’s disease. In addition, neuroinformatics is a field that studies neuroscience and information technology. This integration allows the storage of neurological data in the form of databases. The neuroinformatics market is expected to grow at the second-highest growth rate during the forecast period.
Request a free sample copy or view report summary: Neurodiagnostics Market Report
Increased life expectancy has resulted in an increased geriatric population across the globe. The prevalence of aging-related neurological diseases such as Alzheimer’s disease and Parkinson’s disease is on the rise. The diagnosis of these diseases includes neuroimaging, in vitro diagnosis, and neuroinformatics.
CT and MRI are the most commonly used imaging techniques across the globe, which are mainly used to detect brain abnormalities.
Neurological biomarkers are extremely promising as they provide a direction to the diagnostic studies. Although currently, no commercial biomarker is available in the market, extensive clinical research is happening to find out the perfect combinations of the biomarkers.
North America held the major market share of around 35.8% in 2023 and will retain its top position during the forecast period. On the other hand, Asia Pacific will exhibit the highest CAGR of 4.5% over the forecast period.
Grand View Research has segmented the global neurodiagnostics market report based on technology, end use, and region
Neurodiagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
Neuroimaging Technologies
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging (PET, SPECT)
Near infrared spectroscopic imaging (NIRS)
Electro-encephalography (EEG)
Magneto-encephalography (MEG)
Voxel based morphometry (VBM)
In Vitro Diagnostics
Neuroinformatics
Neurodiagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals &s Clinics
Diagnostic Laboratories
Imaging Centers
Others
Neurodiagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Neurodiagnostics Market
Canon Medical Systems Corporation
Siemens Healthineers AG
Koninklijke Philips N.V.
Thermo Fisher Scientific, Inc.
FUJIFILM Corporation
Natus Medical Incorporated (Natus)
Lifelines Neuro
Advanced Brain Monitoring, Inc.
NIHON KOHDEN CORPORATION.
F. Hoffmann-La Roche Ltd
GE HealthCare.
Mitsar Co. LTD.
"The quality of research they have done for us has been excellent..."